Dihydroceramide Desaturase 1 (DES1)

Dihydroceramide Desaturase 1; DES1; DEGS1

Dihydroceramide Desaturase 1 (DES1) is mainly located in the endoplasmic reticulum, and catalyzes the conversion of dihydroceramide to ceramide through introduction of a 4,5-trans double bond. Dihydroceramide Desaturase 1 promotes the ceramide synthesis and sphingolipid metabolism, induces the cell apoptosis and autophagy, and regulates endoplasmic reticulum stress. Dihydroceramide Desaturase 1 dysfunction could cause ceramide abnormal accumulation, thereby affecting insulin signaling, leading to insulin resistance and fatty liver. Dihydroceramide Desaturase 1 also causes cancer or some neurological disorders^[1].

References:

[1]. Alsanafi M, et al., Dihydroceramide Desaturase Functions as an Inducer and Rectifier of Apoptosis: Effect of Retinol Derivatives, Antioxidants and Phenolic Compounds. Cell Biochem Biophys. 2021 Sep;79(3):461-475. [Content Brief]

Dihydroceramide Desaturase 1 (DES1) Inhibitor (1)

Dihydroceramide Desaturase 1 (DES1) Related Products (1):

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-163472

PR280	Inhibitor
PR280 is a potent inhibitor of dihydroceramide desaturase 1 (Des1) (IC₅₀=700 nM). PR280 forms hydrogen bonds with the amino acid residues of Des1, and its cyclopropenone group may form a coordination with the iron center, thus stabilizing the binding to the active site of Des1 and inhibiting the sphingosine lipid synthesis pathway of dihydroceramide (dhCer) to form ceramide. PR280 can be used in the study of diseases related to sphingosine lipid metabolism, such as cancer and metabolic diseases.

Name
Email *

	Sorry, but the email address you supplied was invalid.